CMV-MVA Triplex Vaccination

Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
216 patients (estimated)
Sponsors
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Tags
Allogeneic Stem Cell Transplant, Vaccine, Placebo, Randomization
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1776
NCT Identifier
NCT06059391

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.